253-LB: Effect of Combined Low Dose IL-2 plus Polyclonal Tregs in Type 1 Diabetes Patients

Background: Regulatory T cells (Tregs) have been shown to be master regulators of autoimmunity and, as such, Treg cell-based immunotherapeutics have gained increasing interest. We have previously shown that adoptive Treg cell therapy can block autoimmune destruction of beta-islet cells in mouse type...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Diabetes (New York, N.Y.) N.Y.), 2019-06, Vol.68 (Supplement_1)
Hauptverfasser:	DONG, SHEN, MOWERY, CODY T., HEROLD, KEVAN C., GITELMAN, STEPHEN E., ESENSTEN, JONATHAN H., LIU, WEIHONG, LARES, ANGELA P., LEINBACH, ASHLEY S., LEE, MICHAEL R., NGUYEN, VINH Q., PUTNAM, AMY L., YE, JIMMIE, TANG, QIZHI, BLUESTONE, JEFFREY
Format:	Artikel
Sprache:	eng
Schlagworte:	Autoimmunity CD8 antigen Cell activation Diabetes Diabetes mellitus Diabetes mellitus (insulin dependent) Flow cytometry Granzyme B Immunoregulation Insulin Interleukin 2 Islet cells Lymphocytes T Patients Safety
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!